Key clinical point: Folinic acid did not improve rates of severe methotrexate-induced oral mucositis vs. placebo.
Major finding: There were no significant differences in any primary or secondary endpoints in patients treated with folinic acid or placebo.
Study details: Randomized controlled trial of 52 adults receiving methotrexate for GVHD prophylaxis post transplant.
Disclosures: Rabin Medical Center sponsored the trial. Dr. Yeshrun, Dr. Nagler, and Dr. Gilleece reported no relevant conflicts of interest.
Yeshrun M. et al. TCT 2020. Abstract 61.